CS3-03 Combination Antifungals - Is There a Role?  by Tan, B.H.
S6 Concurrent Session 3 – Fungal Infections
10-7 per donor cell in broth mating, respectively. Tn1546-like
elements encoding vanA-type VRE were classiﬁed into ten types,
and most of them contained both IS1216V and IS1542 insertions.
The results suggested that the disseminations of VRE were by
Tn1546-like elements being acquired by the conjugative plasmids
and transferred among E. francium strains.
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CS3-01 Cryptococcosis in AIDS Patients: From Research
to Practices in Resource-Limited Settings
Somnuek Sungkanuparph*. Division of Infectious Diseases,
Department of Medicine, Faculty of Medicine Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
Cryptococcosis is the most common life-threatening fungal infec-
tion among AIDS patients in resource-limited settings. It almost
always occurs in patients with severe immunodeﬁciency and
HIV-infected patients in resource-limited settings usually present
with advanced HIV disease. The mortality rate from cryptococ-
cosis in these settings is relatively high even with antifungal
treatment. Several randomized clinical trials have demonstrated
that primary prophylaxis with ﬂuconazole reduces the incidence
of cryptococcosis in patients with advanced HIV disease, partic-
ularly those with CD4 counts <100 cells/μL. A controlled trial in
Thailand also demonstrated a survival beneﬁt. Although primary
prophylaxis for cryptococcosis is not generally recommended in
high-income countries, it may be more beneﬁcial in resource-
limited countries because of the higher incidence of disease
and the limited capacity of diagnosis and treatment. Primary
prophylaxis with ﬂuconazole is recommended in Thailand for
years while the recent WHO guidelines for essential prevention
of opportunistic infections suggest that azole prophylaxis should
be considered for HIV-infected patients with WHO clinical stage 4
or CD4 <100 cells/μL, whether they are on antiretroviral therapy
(ART) or not. A study of antifungal susceptibilities of Cryptococ-
cus neoformans isolates has shown that the MICs of ﬂuconazole
are not higher with ﬂuconazole prophylaxis.
Treatment of choice for cryptococcosis includes combination
of amphotericin B and ﬂucytosine for 2 weeks and followed
with ﬂuconazole 400 mg/day for 8-10 weeks. However, ﬂucyto-
sine is not available in most developing countries. Prior studies
of combination of amphotericin B and ﬂuconazole had shown
controversial outcomes. A recent randomized, phase II trial in
Thailand and the United States has compared the safety and
efﬁcacy of amphotericin B with that of amphotericin B plus
low-dosed or high-dosed ﬂuconazole. There are no differences
in treatment-related toxicities among the three arms. A trend
towards better outcomes in the combination therapy arms is
seen at days 42 and 70. These results have signiﬁcant treatment
implications and should be validated in a randomized phase III
trial.
In the pre-ART era, relapses were frequent and secondary pro-
phylaxis with ﬂuconazole had been recommended for life-long.
The studies of ART initiation among patients with cryptococcosis
in resource-limited settings have shown that the incidence of new
cases and rate of relapsed disease are dramatically reduced, and
the survival has markedly increased. Prospective studies from
resource-limited settings had also demonstrated that discontin-
uation of secondary prophylaxis is safe when patients achieve
successful immune restoration from ART.
Cryptococcal immune reconstitution inﬂammatory syndrome (C-
IRIS) is characterized a clinical deterioration of cryptococcosis
following initiation of ART. Some studies report that C-IRIS is
observed more frequently in severely immunocompromised pa-
tients with disseminated infection or early ART initiation after
cryptococcosis. This may partly explain the high incidence of
C-IRIS in resource-limited settings. However, a standard case
deﬁnition of C-IRIS has not been available. The International
Network for the Study of HIV-associated IRIS has been working
for the practical case deﬁnition of C-IRIS to provide a tool for
clinical use, particularly in resource-limited settings, and future
epidemiologic studies.
CS3-02 Harnessing Multidrug Resistance Gene Expression
for Effective Antifungal Strategies by a Natural
Product Berberine
Lixin Zhang*. Institute of Microbiology, Chinese Academy of
Sciences, Beijing, China
The effectiveness of existing drugs is increasingly compromised
by the emergence of drug-resistant pathogens. Upregulating
multidrug-resistance (MDR) pumps, which confers enhanced re-
sistance to chemically unrelated alien substances, is a major
source of microbial drug resistance. A major challenge in devel-
oping efﬁcacious antibiotics against drug-resistant pathogens is
to identify compounds that could counteract MDR functions. In
the human pathogen Candida albicans, Mdr1p plays a key role in
azole-resistant clinical isolates.
Here we report an unexpected consequence of MDR1 upreg-
ulation: it confers enhanced sensitivity to a natural product,
berberine. This effect of MDR1 overexpression is at least in part
due to enhanced accumulation of berberine inside cells. In sup-
port of this notion, a number of berberine structural analogues
exhibited a similar MDR1-dependent antifungal activity. We also
show that berberine is indeed highly efﬁcacious in inhibiting
the growth of azole-resistant clinical C. albicans isolates with
upregulated MDR1 from HIV infected patients. Our study reveals
a novel function of MDR1 in raising sensitivity of drug-resistant
fungal pathogens to selected natural products. Thus, the drug
resistance phenotype conferred by MDR1 overexpression could be
harnessed through the use of MDR1-dependent cytotoxic agents,
such as berberine, for effective antifungal strategies.
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Traditionally, antibiotics have been combined to treat polymicro-
bial infections, in initial therapy, and to prevent the emergence
of resistance. For years, the hope has been that combining anti-
fungals would produce the same effects. In medical mycology,
however, very few combinations have made it to standard recom-
mendations. The combination of amphotericin B and ﬂucytosine
in the initial treatment of cryptococcal meningitis is a case in
point. That combining antifungals is not yet quite standard prac-
tice stems from problems in interpreting the literature. The same
combination of drugs have produced different results in different
laboratories! This likely has to do with the fact that most of the
tests are not standardized. Further, the best clinical data come
only from retrospective studies. In this talk the literature on
combinatino antifungals will be reviewed.
CS3-04 The Echinocandins and Formulary Decision
Mamie Hui *. Department of Microbiology, the Chinese University
of Hong Kong, Hong Kong, China
Invasive fungal infections have always been a difﬁcult to treat
infectious diseases with high mortality. This is due to the im-
munocompromised state of the patients as well as toxicities
of antifungal treatments. Traditionally, only the azoles and the
polyenes are available for treatment of these patients. Recently,
a novel class of antifungal agents, the echinocandins, have
emerged with promising safety proﬁles. These agents act by
inhibiting the synthesis of 1,3-β-D-glucan of fungal cell wall.
